PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor.

被引：0
|
作者：
Ding, Liya [1 ]
Wang, Qiwei [1 ]
Kearns, Michael [1 ]
Jiang, Tao [1 ]
Konstantinopoulos, Panagiotis [1 ]
Matulonis, Ursula [1 ]
Zhao, Jean [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CLINICAL CANCER RESEARCH | 2020年 / 26卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA17
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] PARP INHIBITION INCREASES IN THE SUPPRESSIVE CAPACITY OF TUMOR-ASSOCIATED TREGS IN A BRCA1-DEFICIENT MODEL OF OVARIAN CANCER
    Falcon, Daniel
    Kinjyo, Ichiko
    Adams, Sarah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1155 - A1155
  • [2] PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
    Ding, Liya
    Kim, Hye-Jung
    Wang, Qiwei
    Kearns, Michael
    Jiang, Tao
    Ohlson, Carolynn E.
    Li, Ben B.
    Xie, Shaozhen
    Liu, Joyce F.
    Stover, Elizabeth H.
    Howitt, Brooke E.
    Bronson, Roderick T.
    Lazo, Suzan
    Roberts, Thomas M.
    Freeman, Gordon J.
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    Zhao, Jean J.
    CELL REPORTS, 2018, 25 (11): : 2972 - +
  • [3] Intermittent treatment with the PARP inhibitor olaparib delays tumor development in BRCA1-deficient mice
    Liby, Karen T.
    To, Ciric
    CANCER RESEARCH, 2014, 74 (23)
  • [4] CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
    Higuchi, Tomoe
    Flies, Dallas B.
    Marjon, Nicole A.
    Mantia-Smaldone, Gina
    Ronner, Lukas
    Gimotty, Phyllis A.
    Adams, Sarah F.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (11) : 1257 - 1268
  • [5] Immunogenicity of BRCA1-deficient ovarian cancers is driven through DNA sensing and is augmented by PARP inhibition
    Bruand, M.
    Barras, D.
    Mina, M.
    Lanitis, E.
    Chong, C.
    Dorier, J.
    Walton, J.
    Bassani-Sternberg, M.
    Kandalaft, L.
    McNeish, I. A.
    Swisher, E.
    Delorenzi, M.
    Ren, B.
    Ciriello, G.
    Irving, M.
    Rusakiewicz, S.
    Foukas, P.
    Martinon, F.
    Dangaj, D.
    Coukos, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
    Wang, Qiwei
    Bergholz, Johann S.
    Ding, Liya
    Lin, Ziying
    Kabraji, Sheheryar K.
    Hughes, Melissa E.
    He, Xiadi
    Xie, Shaozhen
    Jiang, Tao
    Wang, Weihua
    Zoeller, Jason J.
    Kim, Hye-Jung
    Roberts, Thomas M.
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    Dillon, Deborah A.
    Winer, Eric P.
    Lin, Nancy U.
    Zhao, Jean J.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
    Qiwei Wang
    Johann S. Bergholz
    Liya Ding
    Ziying Lin
    Sheheryar K. Kabraji
    Melissa E. Hughes
    Xiadi He
    Shaozhen Xie
    Tao Jiang
    Weihua Wang
    Jason J. Zoeller
    Hye-Jung Kim
    Thomas M. Roberts
    Panagiotis A. Konstantinopoulos
    Ursula A. Matulonis
    Deborah A. Dillon
    Eric P. Winer
    Nancy U. Lin
    Jean J. Zhao
    Nature Communications, 13
  • [8] PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
    Staniszewska, Anna D.
    Armenia, Joshua
    King, Matthew
    Michaloglou, Chrysiis
    Reddy, Avinash
    Singh, Maneesh
    San Martin, Maryann
    Prickett, Laura
    Wilson, Zena
    Proia, Theresa
    Russell, Deanna
    Thomas, Morgan
    Delpuech, Oona
    O'Connor, Mark J.
    Leo, Elisabetta
    Angell, Helen
    Valge-Archer, Viia
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [9] Identification of BRCA1-deficient ovarian cancers
    Skytte, Anne-Bine
    Waldstrom, Marianne
    Rasmussen, Anders Aamann
    Cruger, Dorthe
    Woodward, Emma R.
    Kolvraa, Steen
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2011, 90 (06) : 593 - 599
  • [10] The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice
    To, Ciric
    Kim, Eun-Hee
    Royce, Darlene B.
    Williams, Charlotte R.
    Collins, Ryan M.
    Risingsong, Renee
    Sporn, Michael B.
    Liby, Karen T.
    CANCER PREVENTION RESEARCH, 2014, 7 (07) : 698 - 707
12345